Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

South America Peripheral Neuropathy Market

ID: MRFR/HC/49650-HCR
200 Pages
Nidhi Mandole
Last Updated: February 06, 2026

South America Peripheral Neuropathy Market Research Report By Type (Diabetic Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy, Idiopathic Peripheral Neuropathy, HIV/AIDS Associated Peripheral Neuropathy), By Treatment (Pharmacological Therapies, Non-Pharmacological Therapies, Others), By End-user (Hospitals and Clinics, Ambulatory Centers, Others), and By Regional (Brazil, Mexico, Argentina, Rest of South America) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

South America Peripheral Neuropathy Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Life Sciences, BY Type (USD Million)
  49.     4.1.1 Diabetic Peripheral Neuropathy
  50.     4.1.2 Chemotherapy-induced Peripheral Neuropathy
  51.     4.1.3 Idiopathic Peripheral Neuropathy
  52.     4.1.4 HIV/AIDS Associated Peripheral Neuropathy
  53.   4.2 Life Sciences, BY Treatment (USD Million)
  54.     4.2.1 Pharmacological Therapies
  55.     4.2.2 Non-Pharmacological Therapies
  56.     4.2.3 Others
  57.   4.3 Life Sciences, BY End User (USD Million)
  58.     4.3.1 Hospitals and Clinics
  59.     4.3.2 Ambulatory Centers
  60.     4.3.3 Others
  61. 5 SECTION V: COMPETITIVE ANALYSIS
  62.   5.1 Competitive Landscape
  63.     5.1.1 Overview
  64.     5.1.2 Competitive Analysis
  65.     5.1.3 Market share Analysis
  66.     5.1.4 Major Growth Strategy in the Life Sciences
  67.     5.1.5 Competitive Benchmarking
  68.     5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  69.     5.1.7 Key developments and growth strategies
  70.       5.1.7.1 New Product Launch/Service Deployment
  71.       5.1.7.2 Merger & Acquisitions
  72.       5.1.7.3 Joint Ventures
  73.     5.1.8 Major Players Financial Matrix
  74.       5.1.8.1 Sales and Operating Income
  75.       5.1.8.2 Major Players R&D Expenditure. 2023
  76.   5.2 Company Profiles
  77.     5.2.1 Pfizer Inc (US)
  78.       5.2.1.1 Financial Overview
  79.       5.2.1.2 Products Offered
  80.       5.2.1.3 Key Developments
  81.       5.2.1.4 SWOT Analysis
  82.       5.2.1.5 Key Strategies
  83.     5.2.2 Johnson & Johnson (US)
  84.       5.2.2.1 Financial Overview
  85.       5.2.2.2 Products Offered
  86.       5.2.2.3 Key Developments
  87.       5.2.2.4 SWOT Analysis
  88.       5.2.2.5 Key Strategies
  89.     5.2.3 Bristol-Myers Squibb Company (US)
  90.       5.2.3.1 Financial Overview
  91.       5.2.3.2 Products Offered
  92.       5.2.3.3 Key Developments
  93.       5.2.3.4 SWOT Analysis
  94.       5.2.3.5 Key Strategies
  95.     5.2.4 AstraZeneca PLC (GB)
  96.       5.2.4.1 Financial Overview
  97.       5.2.4.2 Products Offered
  98.       5.2.4.3 Key Developments
  99.       5.2.4.4 SWOT Analysis
  100.       5.2.4.5 Key Strategies
  101.     5.2.5 Novartis AG (CH)
  102.       5.2.5.1 Financial Overview
  103.       5.2.5.2 Products Offered
  104.       5.2.5.3 Key Developments
  105.       5.2.5.4 SWOT Analysis
  106.       5.2.5.5 Key Strategies
  107.     5.2.6 Teva Pharmaceutical Industries Ltd (IL)
  108.       5.2.6.1 Financial Overview
  109.       5.2.6.2 Products Offered
  110.       5.2.6.3 Key Developments
  111.       5.2.6.4 SWOT Analysis
  112.       5.2.6.5 Key Strategies
  113.     5.2.7 Eli Lilly and Company (US)
  114.       5.2.7.1 Financial Overview
  115.       5.2.7.2 Products Offered
  116.       5.2.7.3 Key Developments
  117.       5.2.7.4 SWOT Analysis
  118.       5.2.7.5 Key Strategies
  119.     5.2.8 Mylan N.V. (US)
  120.       5.2.8.1 Financial Overview
  121.       5.2.8.2 Products Offered
  122.       5.2.8.3 Key Developments
  123.       5.2.8.4 SWOT Analysis
  124.       5.2.8.5 Key Strategies
  125.     5.2.9 Sanofi S.A. (FR)
  126.       5.2.9.1 Financial Overview
  127.       5.2.9.2 Products Offered
  128.       5.2.9.3 Key Developments
  129.       5.2.9.4 SWOT Analysis
  130.       5.2.9.5 Key Strategies
  131.   5.3 Appendix
  132.     5.3.1 References
  133.     5.3.2 Related Reports
  134. 6 LIST OF FIGURES
  135.   6.1 MARKET SYNOPSIS
  136.   6.2 SOUTH AMERICA MARKET ANALYSIS BY TYPE
  137.   6.3 SOUTH AMERICA MARKET ANALYSIS BY TREATMENT
  138.   6.4 SOUTH AMERICA MARKET ANALYSIS BY END USER
  139.   6.5 KEY BUYING CRITERIA OF LIFE SCIENCES
  140.   6.6 RESEARCH PROCESS OF MRFR
  141.   6.7 DRO ANALYSIS OF LIFE SCIENCES
  142.   6.8 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
  143.   6.9 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
  144.   6.10 SUPPLY / VALUE CHAIN: LIFE SCIENCES
  145.   6.11 LIFE SCIENCES, BY TYPE, 2024 (% SHARE)
  146.   6.12 LIFE SCIENCES, BY TYPE, 2024 TO 2035 (USD Million)
  147.   6.13 LIFE SCIENCES, BY TREATMENT, 2024 (% SHARE)
  148.   6.14 LIFE SCIENCES, BY TREATMENT, 2024 TO 2035 (USD Million)
  149.   6.15 LIFE SCIENCES, BY END USER, 2024 (% SHARE)
  150.   6.16 LIFE SCIENCES, BY END USER, 2024 TO 2035 (USD Million)
  151.   6.17 BENCHMARKING OF MAJOR COMPETITORS
  152. 7 LIST OF TABLES
  153.   7.1 LIST OF ASSUMPTIONS
  154.     7.1.1
  155.   7.2 South America MARKET SIZE ESTIMATES; FORECAST
  156.     7.2.1 BY TYPE, 2025-2035 (USD Million)
  157.     7.2.2 BY TREATMENT, 2025-2035 (USD Million)
  158.     7.2.3 BY END USER, 2025-2035 (USD Million)
  159.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  160.     7.3.1
  161.   7.4 ACQUISITION/PARTNERSHIP
  162.     7.4.1

South America Life Sciences Market Segmentation

Life Sciences By Type (USD Million, 2025-2035)

  • Diabetic Peripheral Neuropathy
  • Chemotherapy-induced Peripheral Neuropathy
  • Idiopathic Peripheral Neuropathy
  • HIV/AIDS Associated Peripheral Neuropathy

Life Sciences By Treatment (USD Million, 2025-2035)

  • Pharmacological Therapies
  • Non-Pharmacological Therapies
  • Others

Life Sciences By End User (USD Million, 2025-2035)

  • Hospitals and Clinics
  • Ambulatory Centers
  • Others

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions